GlassScriptPhysician profile
Wesley C Green
NPI 1851736037
$9,243.63
in general payments reported to CMS, 2019-2025
21 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $366 · 2021: $1,125 · 2022: $1,955 · 2023: $1,941 · 2024: $1,747 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,535 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.91 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,863.07 | 2020-2025 | Hydrus Microstent, Clareon, Unity |
| Sight Sciences, INC. | $1,706.19 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,665.22 | 2022-2025 | |
| Glaukos Corporation | $929.38 | 2019-2025 | Idosetr, Istent Infinite |
| New World Medical,INC. | $546.31 | 2021-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $444.52 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.10 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $151.63 | 2022-2025 | Vyzulta, Infuse |
| Nova Eye, INC. | $142.83 | 2023 | |
| Thea Pharma INC. | $123.65 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $87.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $74.71 | 2022-2023 | |
| Coopervision INC. | $74.23 | 2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $63.36 | 2020-2023 | Cequa |
| Oyster Point Pharma, INC. | $33.48 | 2024 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.63 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $31.12 | 2023 | Acthar |
| Ocular Therapeutix, INC. | $24.27 | 2023 | Dextenza |
| Eyevance Pharmaceuticals LLC | $17.48 | 2022 | |
| Rxsight INC | $14.95 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.